BioSpace News Archive

- Multiple milestones expected in the Fourth Quarter from the Company’s ARC pipeline including Phase 3 data from the pivotal SIERRA trial for Iomab-B and Actimab-A combination trials with CLAG-M and venetoclax - Ad hoc interim analysis from SIERRA to be completed by year end

Evecxia Therapeutics, Inc., a biopharmaceutical company focused on treating patients suffering from disabling neuropsychiatric conditions for which current therapies are inadequate, today announced Thomas H. Aasen has joined its Board of Directors. Mr. Aasen is a financial executive with over thirty years of professional experience, including financial management positions in four publicly held life science co

Expertly annotated patient samples from world-class clinical research facility Samples used to advance development of the world’s first 3D genomic severity test for COVID-19 disease built using the EpiSwitch™ platform Goal is to provide insight into a wide range of COVID-19 responses, from mild to severe Adds to Oxford BioDynamics’ growing bank of 500+ procured samples from cohorts around the world

Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2020 financial results and provide a corporate update on Wednesday, November 4, 2020 at 4:30 p.m. Eastern/1:30 p.m. Pacific. Conference Call and Webcast: Wednesday, November 4, 2020 @ 4:30 p.m. Eastern/1:30 p.m. P

Finch Therapeutics Presents Data from Its Positive PRISM3 Trial of CP101 in Recurrent C. difficile Infection at Two Leading Medical Conferences PRISM3 data presented at the annual meetings of the United European Gastroenterology and the American College of Gastroenterology Late-breaker oral presentations expand on previously announced positive topline data showing that CP101 met the primary efficacy endpoint with statistically significant improv

Saphetor, a global precision medicine company and the creator of VarSome, the emerging global standard platform for human genome data, announced a partnership with Roche Turkey.

XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from XOMA, has advanced to the Phase 2 development stage, triggering a $25 million milestone payment from Novartis.

Rapid-result testing enables symptomatic patients who test negative for COVID-19 to access testing and care for influenza and other seasonal illnesses at MinuteClinic

Accuray Incorporated (NASDAQ: ARAY), a pioneer in the robotic stereotactic radiosurgery (SRS) field announced today a collaboration with Brainlab, a Munich, Germany based market leader in digital surgery and precision radiotherapy that will enhance and expand the Accuray CyberKnife® treatment platform for the neuro-radiosurgery market.

Former Merck Executive and Vaccine Industry Leader to Drive Development Opportunities for Codagenix’s Diverse Pipeline, Including Vaccine Candidates for SARS-CoV-2 and RSV